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ABSTRACT
Aim of study. The aim of this study was to collect and analyse data on relapsing-remitting multiple sclerosis (RRMS) patients 
receiving disease-modifying therapies (DMTs) in Poland. 
Material and methods. This observational, multicentre study with prospective data collection included RRMS patients recei-
ving DMTs reimbursed by the National Health Fund (NFZ) in Poland, monitored by the Therapeutic Programme Monitoring 
System (SMPT). Demographic profiles, disability status, and treatment modalities were analysed.
Results. Data from 11,632 RRMS patients (from 15,368 new prescriptions) was collected including 10,649 patients in the first-
-line and 983 in the second-line therapeutic programme of DMTs. The proportion of females to males was 2.39 in the first-line 
and 1.91 in the second-line. The mean age at DMTs start was 36.6 years in the first-line and 35.1 in the second-line. The median 
time from the first symptoms to MS diagnosis was 7.4 months, and from MS diagnosis to treatment it was 18.48 months. A total 
of 43.4% of MS patients started DMT during the 12 months following diagnosis. There was a positive correlation between the 
duration from MS diagnosis to the start of DMT and a higher initial EDSS value [correlation 0.296 (p < 0.001)]. About 10% of 
patients stopped DMTs. In Poland, about one third of all MS patients are treated in both lines of therapeutic programmes, and 
the choice of first-line treatment depends on the region of the country.
Conclusions. In Poland there is a need to increase MS patient access to DMTs by improving the organisation of therapeutic 
programmes.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system leading to 
oligodendrocyte degeneration and neuron destruction. MS 
affects mainly young adults and is a leading cause of long-term 
disability. The estimated number of people suffering from MS 
worldwide is approximately 2.3 million [1, 2]. In Poland, there 
are around 45,000 patients, with a prevalence of approximately 
110–115/100,000 residents [3, 4].
In Poland, disease-modifying therapies (DMTs) for 
relapsing-remitting multiple sclerosis (RRMS) patients are 
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reimbursed by the National Health Fund (NFZ) and monitored 
by the Therapeutic Programme Monitoring System (System 
Monitorowania Programów Terapeutycznych- SMPT), available 
online on the NFZ website. 
The purpose of this study was to collect and analyse data on 
the demographic profiles, diagnostic and treatment modalities 
in patients with RRMS receiving DMTs in the first-line and 
second-line programmes reimbursed by the NFZ, treated in 
all MS centres in Poland. 
Material and methods
This observational, multicentre study with prospective 
data collection was performed in all RRMS patients treated 
with DMTs, diagnosed according to McDonald’s 2010 criteria. 
The first- and second-line drug programmes were initiated 
in 2004 and 2013, respectively. Data from patients treated in 
the drug programmes was collected prospectively in SMPT 
from 2014 to January 2018. SMPT is a programme available 
on the NFZ website, which is used to maintain electronic do-
cumentation of the implementation and monitoring of drug 
programmes. SMPT records and stores information about 
Polish RRMS patients from 128 MS treatment centres for the 
first-line, and from 59 centres for the second-line.
The first-line treatment includes: interferon beta (IFNβ) 
since 2004, glatiramer acetate (GA) since 2005, pegylated in-
terferon beta (PEG) and dimethyl fumarate (DMF) since 2016, 
teriflunomid (TER) and alemtuzumab (ALE) since 2017. The 
IFNβ drug group includes subcutaneous and intramuscular 
IFNβ 1a and subcutaneous IFNβ 1b. 
Within the second-line treatment, two drugs are available: 
natalizumab (NAT) and fingolimod (FTY), both since 2013. 
The RRMS patients are included in the NFZ drug pro-
grammes according to clear rules. In the first-line programme, 
patients must have experienced at least one relapse or have 
shown at least one new gadolinium (GD+) lesion on MRI in 
the preceding 12 months before qualification. An Expanded 
Disability Status Scale (EDSS) score of less than 5.0 points is 
also needed. Changing drugs within the first-line is allowed 
in the case of adverse effects or partial treatment failure. For 
patients in whom first-line therapy is ineffective, second-line 
treatment is indicated. 
To become qualified to the second-line, patients must meet 
the following criteria: no response to a complete cycle (lasting 
a minimum of 12 months) of the first-line DMT, defined as 
the fulfilment of both these two conditions: 
1: two or more moderate relapses requiring administration 
of steroids (an increase of 1–2 points in EDSS score) or one 
severe relapse after six months of treatment (an increase in 
EDSS score higher than 2 points) 
and
2: new lesions on MRI (minimum two GD+ lesions or 
minimum three new T2- lesions) performed every 12 months 
of therapy. 
In rapidly evolving severe relapsing remitting 
MS (RES MS), NAT has been administered since 2013 and 
ALE since 2017; FTY for RES MS was not funded until 2018. 
To be treated as RES MS, patients must have active disease and 
the disease activity must meet both clinical and radiological 
criteria, the same as in the second-line treatment programme.
After each 12 months of treatment in both drug program-
mes, an evaluation of the treatment efficacy, which determines 
whether a patient can continue on the treatment or should be 
switched to another drug, is carried out. DMTs should be di-
scontinued in cases of secondary progressive MS development. 
In the first-line programme, the clinical and radiological 
disease activity evaluations carried out every 12 months whi-
le on treatment allowed us to distinguish five groups of MS 
disease activity: 
 — Group 0: no substantial clinical and radiological signs of 
disease activity
 — Group A: 1 new T2 or 1 new GD+ lesion and 1 relapse 
Group B: 2 new T2 or 1 new GD+ and 1 relapse with EDSS 
worsening ≥ 1.0
 — Group C: 2 new T2 or 1 new GD+ and 2 relapses with 
EDSS worsening ≥ 1.0
 — Group D: 3 new T2 or 2 new GD+ and 2 new relapses with 
EDSS worsening ≥ 1.0 
Our study was approved by the Regional Medical Ethics 
Committee (the Medical University of Bialystok). Written 
consent to use the data for scientific research was obtained 
from the President of the NFZ. Every patient undertaking 
treatment reimbursed by NFZ consented to the collection of 
data in SMPT. We received anonymous data from the NFZ, 
thus preventing identification of the patients. 
Statistical analysis 
The data provided by the NFZ corresponded to drug mo-
nitoring records. For the analysis, a prescription corresponded 
to the uninterrupted period of time during which a patient 
received a specific DMT drug was used. From the records, 
every combination of patient and DMT start date constituted 
the prescription presented in Table 1. Each evaluation was 
described by patient characteristics (sex, age at DMT start, 
duration from first symptoms to diagnosis, duration from diag-
nosis to DMT start, EDSS, MS centre, drug name, treatment 
line, DMT start date), and follow-up (duration in months). 
A descriptive analysis of the DMTs was carried out to provide 
a general characterisation of DMT, and time evolution of DMT 
use. In addition, regional variations were studied in terms of 
disease prevalence (2017 census data for population size), and 
variation in first-line DMT choices. Evaluation of the clinical 
and radiological disease activity was run by the comparison 
of record pairs delimiting periods of 12 months. Evaluation 
relied on the estimation of the following responses: number of 
relapses, number of relapses with EDSS worsening over 1 point, 
number of new T2 lesions, and number of new GD+ lesions. 
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This allowed us to estimate MS disease activity category as 
being in Group 0, Group A, Group B, Group C or Group D.
Results 
Data from 11,632 MS patients was collected (including 
15,368 prescriptions). Of these, 10,649 patients (14,259 pre-
scriptions) were in the first-line and 983 patients (1,109 pre-
scriptions) were in the second-line therapeutic programme 
of DMTs. The proportion of females to males was 2.39 in the 
first-line and 1.91 in the second-line. A significantly higher 
percentage of men was treated in the second-line programme 
than in the first-line (+1.5 to +2% - significant Chi2 indepen-
dence test). The mean age at DMTs start was 36.6 years in the 
first-line and 35.1 in the second-line. The median time from 
the first symptoms to MS diagnosis was 7.4 months, and from 
MS diagnosis to treatment was 18.48 months. A total of 43.4% 
of MS patients started DMT during the 12 months from diag-
nosis. Patient characteristics are presented in Table 1.
There was a positive correlation between the duration from 
MS diagnosis to the start of DMT and disability progression. 
The longer the time taken to start treatment, the higher the 
initial EDSS value (correlation 0.296 (p < 0.001). Median 
EDSS at initiation of the first-line therapy was 1.5, and 3.0 at 
initiation of the second-line therapy. 
During the study, 368 patients (35% of all subjects treated 
in the second-line) from the first-line were switched to the 
second-line because of the ineffectiveness of the first-line 
DMTs. The rest of the patients in the second-line were those 
with RES MS or ones who continuing treatment after parti-
cipating in clinical trials. The first-line therapies that were 
the most frequently switched to the second-line were IFNβ 
(61% of all escalations to the second-line) and GA (33.7% of 
all escalations to the second-line). A total of 10% of patients 
from the first-line and 8% from the second-line stopped the 
DMTs. In the first-line, the most common causes for aborting 
treatment were lack of treatment efficacy (44.9%), and patient 
resignation (34.3%). In the second-line they were patient resig-
nation (40%), lack of treatment efficacy (27.1%), and adverse 
events (27.1%) (Fig. 1). 
Poland  is divided into 16  voivodeships (provinces), 
which differ in their number of inhabitants and population 
density. Taking into account the number of inhabitants in 
individual voivodeships, the largest percentage of patients 
received DMTs in mazowieckie, łódzkie, małopolskie, wielko-
polskie, and świętokrzyskie. The smallest number of patients 
received MS treatment in lubuskie, warmińsko-mazurskie, 
zachodniopomorskie, and podlaskie. The number of patients 
treated in individual voivodeships in relation to the number 
of all inhabitants is shown in Figure 2. The choice of first-line 
treatment depended on the region of the country. Opolskie 
and małopolskie had higher use of DMF, podkarpackie and 
dolnośląskie had higher use of interferon beta. Geographical-
ly close regions had similar first DMTs choice (for example 
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Lack of treatment 
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Pregnancy 
Adverse events 
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Figure 1. Causes for aborting DMTs treatment in first and second-
-line drug programmes
Figure 2. Number of new prescriptions of DMTs in individual voivodeships in relation to total number of inhabitants
śląskie, małopolskie, opolskie) (Fig. 3). A similar analysis was 
performed in the second-line programme, but no geographical 
differences in treatment preferences were shown. 
The number of new first-line DMTs prescriptions, recor-
ded within the SMPT, increased every year. It was negligible 
before 2009, low until 2011, substantial and stable between 
2012 and 2014, and has increased greatly since then. INFβ 
was the main drug from 2009 to 2016. The introduction of 
DMF in MS therapy (2016) was associated with a reduction of 
INFβ treatment, while other new DMTs remained marginally 
used (PEG, TER, ALZ). GA has been the second most used 
DMT, relatively stable, representing approximately 20% of 
new prescriptions every year. The use of second-line DMTs 
has remained stable since their introduction in 2013, with 
about one third of patients treated with NAT and two thirds 
with FTY (Fig. 4, 5).
The results of the analysis of clinical and radiological 
disease activity in the first-line programme are presented in 
Table 2. The annual evaluations comparing current evaluation 
to the preceding evaluation allowed 24,872 MS disease activity 
assessments, of which 7,780 were obtained after 12 months 
of treatment. After a year of treatment, the vast majority of 
patients did not report MS disease activity (7,410 observations, 
i.e. 95% of patients at that time). 370 reported MS disease acti-
vity, and only 0.4% were eligible to the second-line treatment 
(30 patients in MS disease activity category D). The number
of evaluations decreased with time (Table 2), and the propor-
tion of any MS disease activity was relatively stable: 91–96%
of patients did not report any MS disease activity during the
year (2–4% evidenced categories A and B, while less than
1% corresponded to categories C and D). Therefore, a small
number of RRMS patients with MS disease activity, while on
the first-line of DMTs treatment, met the restrictive criteria
to qualify to the second-line (Group D in Tab. 2).
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 Figure 3. Regional differences in prescriptions of INF, GA and DMF from 2012 to 2017
Discussion
 Real-life MS population studies are powerful tools for 
providing meaningful information on disease epidemiology, 
the social and economic impact of the disease, and medication 
effectiveness. Real-world data helps the national regulatory 
authorities to improve the quality of care of MS patients and 
to make relevant decisions about healthcare programmes [5].
This study is the first one to have enrolled all RRMS pa-
tients treated with DMTs reimbursed by the NFZ in Poland. 
The mean age of participants and the sex ratio are similar 
to previously reported observations from Poland and other 
countries [1–10]. Interestingly, we found that a significantly 
higher percentage of men was treated in the second-line pro-
gramme than in the first-line. Analysis of the MSBase registry 
showed that men with RRMS had faster and shorter time-to-
-EDSS points 3 and 6 compared to women [11]. It has also
been shown that men are more likely to develop more severe
relapses with a relatively higher risk of incomplete remission; 
women are more prone to have relapses, but they are also
relatively more likely to recover completely [11].
Compared to previous studies, we found a slightly shorter 
interval between the occurrence of the first symptoms and MS 
diagnosis [3, 4, 6]. The diagnostic process is probably quicker 
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Figure 4. Number of new prescriptions of DMTs in first and second-line drug programmes
Figure 5. Percentage of new prescriptions of DMTs in first-line drug 
programme
Table 2. Number of completed evaluations of any MS disease activity category  
Category   Months ∑
12 18 24 30 36 42 48   51+
0 7410 867 4013 705 2962 656 2334 4791 23738
A  180 34 94 19 57 14 45 83 526
496 17
95
B  158 42 98 19 69 9 35 66
C  2 1 3 1 3 0 0 7
D  30 4 19 1 12 2 10 17
∑ 7780 948 4227 745 3103 681 2424 4964 24872
Number of complete evaluations regarding MS disease activity category (0: no substantial clinical or radiological signs of disease activity; A: 1 new T2 or 1 new GD+ lesion and 1 relapse; B: 2 new T2 or 1 new 
GD+ and 1 relapse with EDSS worsening ≥ 1.0; C: 2 new T2 or 1 new GD+ and 2 relapses with EDSS worsening ≥1; D: 3 new T2 or 2 new GD+ and 2 new relapses with EDSS worsening ≥ 1) and number of 
months. E.g. 94 annual evolutions were categorised as MS disease activity A, 24 months after the prescription started (± 3 months, therefore between 21 and 27 months). ∑ — number of evaluations (evaluation 
visits) of any category (column margin) and at any given time (row margin) 
due to more efficient use of the McDonald diagnostic criteria, 
better access to MRI, and increased awareness among physicians 
about the course of MS and the possibilities for early treatment 
[12]. In our study, the median time from MS diagnosis to start 
of the first DMT was 14.8 months, and in 43.3% of patients the 
first DMT had begun within 12 months of diagnosis. The value 
of the median time from diagnosis to start of the first DMT was 
probably increased by the inclusion of patients with benign MS 
to the first-line programme. According to the rules (i.e. patients 
must experience at least one relapse or have at least one GD+ 
lesion on MRI in the preceding 12 months), some patients with 
benign RRMS are included into the programme many years after 
diagnosis. In our study, the longest time from diagnosis to the 
initiation of the first DMT was 45.7 years.
We should take into account that in patients with RRMS 
it is important to start DMTs as early as possible, because the 
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treatment is most effective in the early stages of the disease. 
In our study, we found that a longer time from MS diagnosis 
to start of treatment was related to a higher initial EDSS 
value. Moreover, recent studies have shown that in active 
MS patients treated with NAT or FTY, a baseline EDSS of 
less than 3.0 increased the probability of remaining disease 
activity-free [13–16]. It was also found that initial treatment 
with highly effective therapies, compared to initial treatment 
with injectable agents, was associated with a lower risk of 
conversion to secondary progressive MS [17]. In our study, the 
baseline EDSS at the beginning of treatment in the second-line 
programme was 3.0. 
It is undeniable that Polish RRMS patients start DMTs, 
especially second-line medications, too late. In Poland in 
January 2018 only 8.8% of all patients were being treated in 
the second-line programme, because only a small group of 
patients met the restrictive criteria of the second-line drug 
programme. In 2013, in Norway 39%, in Sweden 31.8%, in 
Denmark 29.5%, and in France about 20% of MS patients 
were being treated with second-line medications [18]. In 
our study, IFNβ and GA were more frequently switched to 
the second-line therapies because of the ineffectiveness than 
first-line oral medications, but this finding may be related to 
the fact that first-line injectable drugs were used much longer 
in the drug programme (> 4 years) than oral ones (< 2 years). 
INFβ has been the main DMT used until 2016. For example 
in 2015, 75% of MS patients in the first-line were treated with 
INFβ. But in 2017, DMF was the most common drug used in 
MS therapy. On the other hand, GA has been used at a constant 
rate of between 12% and 25% of first-line MS therapy.
Clinical and radiological analysis of disease activity, done 
in our study, showed that more patients with MS disease activi-
ty may be switched from the first-line to the second-line, if less 
restrictive criteria of therapy escalation are used. According 
to the new ECTRIMS/EAN, in the case of the presence of 
early disease activity (i.e. relapses and/or disability progres-
sion and/or MRI activity at 6/12 months), a more efficacious 
drug should be offered to MS patients who are treated with 
injectable agents [19].
In addition, in Poland a delay in reimbursement of inno-
vative therapies is observed. In our country, the time between 
medication approval by the European Medicines Agency and 
drug reimbursement is more than 15 months. For comparison, 
that time is less than three months in Bulgaria, Germany, Italy, 
Lithuania, Malta, and Norway [20].
The most prosperous voivodeships (mazowieckie, wielko-
polskie, małopolskie) are the ones with the highest populations 
and highest proportions of MS patients receiving DMTs. Inte-
restingly, we found that the choice of the first-line treatment 
depends on the region. Geographically close regions had 
similar drug choices even though all MS centres in Poland 
have the same drug programmes. No evidence-based criteria 
exist to inform the choice among different first-line DMTs. 
The choice of first therapy is challenging and depends on the 
neurologist’s and patient’s preferences.
In Poland, the rate of MS prevalence is approximately 
110–115/100,000 residents [3, 4]. Taking into account the 
results obtained in this study, it can be assumed that in our 
country there are about 45,000 MS patients. This means that 
in January 2018 in Poland, about one third of all MS patients 
were being treated in both DMT line programmes. According 
to BAROMETER 2015, the total population of RRMS patients 
treated with DMTs was 80% in Austria, Sweden, and Switzer-
land; 70% in Belgium and France; and 65% in Greece [20]. In 
Germany (in 2013), 69% of MS patients received DMTs [18, 
21]. These differences are mainly a consequence of wealth 
inequality across the European countries and the impact 
of DMTs on health budgets. Additionally, limited access to 
immunomodulatory therapy in Poland is associated with the 
restrictive reimbursement criteria established by the NFZ and 
the low efficiency of MS centres, which is partly due to a lack 
of neurologists and MS nurses. 
Conclusions
This is the first observational, multicentre study with 
prospective data collection analysing diagnostic and treatment 
modalities and the demographic profile of all RRMS patients 
receiving DMTs reimbursed by the NFZ in Poland. The results 
show that about one-third of all Polish MS patients are treated 
with DMTs. Our study highlights the long interval between 
disease diagnosis and DMTs initiation, and the low percentage 
of patients treated with second-line medications. It is necessary 
to increase the access of MS patients to DMTs by improving 
the organisation of the drug programmes. 
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